Clinical Trial Update: A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is an update on a Phase 1/2 clinical trial evaluating the vaccine PDS0101 alone or in combination with pembrolizumab for locally advanced HPV-positive orop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hpv-related Oropharyngeal Cancer
• Oropharyngeal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• PDS0101

Snippet

Sponsor: Mayo Clinic | Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-14